Skip to main content
TipRanks
Go Ultimate75% OFF

BrainCool AB (BRAIN) AI Stock Analysis

0 Followers
SE:BRAIN

BrainCool AB

(Nasdaq OMX AB:BRAIN)

Select Model
Rating:54Neutral
Price Target:SEK 1.00▼(-16.67% Downside)
Action:reiterated
Date:11/14/26

The score is held back primarily by weak financial performance—negative gross profit, heavy cash burn, and ongoing losses—despite a low-debt balance sheet. Technicals are a clear positive with price above major moving averages and positive momentum indicators, while valuation remains constrained by unprofitability and the absence of a dividend.

Positive Factors
Revenue GrowthStrong trailing revenue growth indicates increasing commercial activity and customer demand for the company’s products. If maintained, this expansion can improve operating leverage, support broader market adoption, and provide a larger base from which future profitability may develop.
Negative Factors
Negative Gross ProfitNegative gross profit means current revenue does not cover the direct cost of delivering products, making growth economically dilutive rather than inherently value creating. Sustainable improvement requires significant changes in pricing, product economics, or costs before higher sales can translate into durable earnings.

BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)

-25%0%25%50%75%100%125%SE:BRAIN+108.70%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 473.85M
Dividend Yield
―
Average Volume (3M)
451.22K
Price to Earnings (P/E)
-13.0
Beta (1Y)
0.41
Revenue Growth
0.04%
EPS Growth
34.45%
Country
Sweden
Employees
15
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

BrainCool AB Business Overview & Revenue Model

Company Description

BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company cat...

How the Company Makes Money

BrainCool makes money primarily by selling and/or leasing its temperature management systems to hospitals and other healthcare providers and by generating recurring revenue from disposable consumables and accessories used together with those systems...

BrainCool AB Financial Statement Overview

Summary

Revenue is growing strongly, but the company remains deeply unprofitable with negative gross profit and very weak margins, alongside sustained negative operating and free cash flow. The balance sheet is a relative positive with zero reported debt and sizable equity, but negative ROE and ongoing cash burn keep overall financial quality speculative.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue43.63M36.21M39.96M23.23M17.59M9.26M
Gross Profit-37.10M-40.88M13.13M12.12M-46.16M-48.93M
EBITDA-26.43M-29.99M-34.03M-49.86M-35.07M-32.16M
Net Income-31.59M-37.05M-44.04M-61.28M-45.61M-38.75M
Balance Sheet
Total Assets167.55M192.38M162.04M133.28M133.67M99.35M
Cash, Cash Equivalents and Short-Term Investments36.28M39.57M31.40M25.06M41.21M13.58M
Total Debt0000035.00M
Total Liabilities14.85M16.58M16.11M21.54M17.44M54.12M
Stockholders Equity152.71M175.80M145.93M111.74M116.23M45.23M
Cash Flow
Free Cash Flow-53.05M-56.49M-70.20M-67.23M-53.67M-35.06M
Operating Cash Flow-51.02M-52.68M-62.64M-61.16M-46.27M-24.25M
Investing Cash Flow-4.77M-6.54M-7.57M-6.17M-7.59M-10.82M
Financing Cash Flow85.23M67.33M76.80M50.93M81.28M36.39M

BrainCool AB Technical Analysis

Technical Analysis SentimentPositive
Last Price1.20

Price Trends

50DMA1.06Positive
100DMA0.92Positive
200DMA0.79Positive

Market Momentum

MACD0.03Negative
RSI68.13Neutral
STOCH95.56Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Positive. The current price of 1.20 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 1.06, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 68.13 is Neutral, neither overbought nor oversold. The STOCH value of 95.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BRAIN.

BrainCool AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:BRAIN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.53B26.699.13%1.71%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.925.89%―17.83%330.94%
SE:PAXSE:PAX57NeutralSEK 1.55B-306.14-1.22%―34.05%-144.96%
SE:BRAINSE:BRAIN54NeutralSEK 473.85M-12.99-19.29%―0.04%34.45%
SE:OSSDSE:OSSD52NeutralSEK 368.38M-7.36――-11.89%-11.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SEDANASE:SEDANA49NeutralSEK 921.85M-26.71-3.88%―0.42%15.03%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:BRAINSE:GETI.BSE:PAXSE:XVIVOSE:SEDANASE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:BRAIN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:BRAINBrainCool AB1.200.61105.13%
SE:GETI.BGetinge AB (UK)277.3074.5836.79%
SE:PAXPaxman AB66.804.807.74%
SE:XVIVOXvivo Perfusion AB196.0031.0018.79%
SE:SEDANASedana Medical AB9.28-0.33-3.43%
SE:OSSDOssDsign AB3.33-7.41-68.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026